Multicenter evaluation of the efficacy and safety of gatifloxacin in Mexican adult outpatients with respiratory tract infections

Advances in Therapy

Volumn 17, Issue 6, 2000, Pages 263-271

  Casillas, J L ^a   Rico, G ^b   Rodriguez Parga D ^b   Mascarenno A ^c   Rangel Frausto, S ^d,e  

^a HOSPITAL DE ESPECIALIDADES   (Mexico)

^b Hospital General Dr Gaudencio Gonzalez Garza   (Mexico)

^c Hospital Regional ISSSTE Culiacán   (Mexico)

^d INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^e Centro Médico Siglo XXI 3er piso   (Mexico)

Author keywords

Acute exacerbations of chronic bronchitis; Acute sinusitis; Community acquired pneumonia; Fluoroquinolones; Gatifloxacin; Respiratory tract infections

Indexed keywords

GATIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CHRONIC BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTRITIS; HEADACHE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEXICO; MULTICENTER STUDY; NAUSEA; PENICILLIN RESISTANCE; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SINUSITIS; STREPTOCOCCUS PNEUMONIAE; VERTIGO;

ACUTE DISEASE; ADMINISTRATION, ORAL; ADULT; AMBULATORY CARE; ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; BRONCHITIS; COMMUNITY-ACQUIRED INFECTIONS; DIZZINESS; DRUG RESISTANCE, MICROBIAL; FEMALE; FLUOROQUINOLONES; HEADACHE; HUMANS; MALE; MEXICO; MIDDLE AGED; NAUSEA; PNEUMONIA; PROSPECTIVE STUDIES; RECURRENCE; RESPIRATORY TRACT INFECTIONS; SAFETY; SINUSITIS; TREATMENT OUTCOME;

EID: 0034463483     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02850009     Document Type: Article

References (31)

1. Respiratory tract infections: Consider the total cost of care
2. Acute respiratory infections: The forgotten pandemic
3. Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy
4. Community-acquired pneumonia
5. Community-acquired pneumonia in adults: Initial antibiotic therapy
6. Guidelines from the Infectious Diseases Society of America. Community-acquired pneumonia in adults: Guidelines for management
7. Acute bronchitis in adults: Commonly diagnosed but poorly defined
8. Acute exacerbations of chronic bronchitis. An international comparison
9. Infectious etiology of acute exacerbations of chronic bronchitis
10. Chronic bronchitis and acute infectious exacerbations
11. Infection in acute exacerbations of chronic bronchitis: A clinical perspective
12. Antibiotic therapy of exacerbations of chronic bronchitis
13. Chronic sinusitis
14. Antimicrobial treatment guidelines for acute bacterial sinusitis
15. Evaluation of the microbiology of chronic sinusitis
16. Three year global experience of the SENTRY Antimicrobial Surveillance Program (1997-1999) monitoring community-acquired respiratory tract infection (CARTI) pathogens: Results from 17,166 strains of S. pneumoniae, H. influenzae, and M. catarrhalis
17. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin
18. Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model
19. Interchangeability of 400-mg intravenous and oral gatifloxacin in healthy adults
20. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers
21. Clinical efficacy and safety of gatifloxacin in S. pneumoniae community-acquired pneumonia: Initial report from TeqCES
22. New concepts in antimicrobial therapy for emergency department infections
23. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new 'respiratory quinolones'
24. Geographic variation in antimicrobial resistance among respiratory pathogens from US outpatients: Initial report from the RESP study of community-acquired respiratory tract infections (CARTI)
25. Differences in susceptibility of S. pneumoniae isolated from patients with community-based respiratory tract infections
26. Once-daily 400 mg oral gatifloxacin (GAT) vs twicedaily 500 mg oral clarithromycin (CLA) in the treatment of community-acquired pneumonia (CAP)
27. A randomized, double-blind, multicenter, comparative study of gatifloxacin vs levofloxacin in the treatment of community-acquired pneumonia
28. Gatifloxacin vs cefuroxime axetil in patients with acute exacerbations of chronic bronchitis
29. Gatifloxacin in the treatment of acute bacterial sinusitis (ABS) in Mexico
30. New classification and update on the quinolone antibiotics
31. Inhibition of the HERG potassium channel by fluoroquinolone antibacterials: Correlation with risk for clinically significant QT interval prolongation